Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
D 7.92 -3.53% -0.29
SCYX closed down 2.61 percent on Monday, April 12, 2021, on 77 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical SCYX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -3.47%
Fell Below 50 DMA Bearish -3.47%
20 DMA Support Bullish -5.99%
50 DMA Support Bullish -5.99%
20 DMA Support Bullish -6.32%
Crossed Above 50 DMA Bullish -6.32%
180 Bullish Setup Bullish Swing Setup -6.32%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.32%
Fell Below 50 DMA Bearish -4.75%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.75%
Older End-of-Day Signals for SCYX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 1 hour ago
20 DMA Resistance about 2 hours ago
Down 3% about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


SCYNEXIS, Inc. Description

SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Eye Drugs Medication Dogs Hepatitis C Eye Disease Hepatitis C Virus Interferon Anti Infectives Cyclophilin Fungal Infection Pegylation Dry Eye Disease Fungal Infections

Is SCYX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.4
52 Week Low 4.2009
Average Volume 508,072
200-Day Moving Average 6.78
50-Day Moving Average 8.45
20-Day Moving Average 8.22
10-Day Moving Average 8.14
Average True Range 0.52
ADX 15.42
+DI 15.82
-DI 20.97
Chandelier Exit (Long, 3 ATRs ) 7.37
Chandelier Exit (Short, 3 ATRs ) 8.57
Upper Bollinger Band 8.94
Lower Bollinger Band 7.50
Percent B (%b) 0.49
BandWidth 17.49
MACD Line -0.01
MACD Signal Line -0.05
MACD Histogram 0.038
Fundamentals Value
Market Cap 89.82 Million
Num Shares 10.9 Million
EPS -0.59
Price-to-Earnings (P/E) Ratio -13.99
Price-to-Sales 1049.19
Price-to-Book 7.31
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.07
Resistance 3 (R3) 9.08 8.80 8.92
Resistance 2 (R2) 8.80 8.59 8.80 8.87
Resistance 1 (R1) 8.51 8.45 8.37 8.50 8.83
Pivot Point 8.23 8.23 8.17 8.23 8.23
Support 1 (S1) 7.94 8.02 7.80 7.93 7.59
Support 2 (S2) 7.66 7.88 7.66 7.55
Support 3 (S3) 7.37 7.66 7.50
Support 4 (S4) 7.36